Last reviewed · How we verify
G-CSF+EPO
G-CSF stimulates neutrophil production while EPO stimulates red blood cell production, together enhancing hematopoietic recovery and tissue oxygenation.
G-CSF stimulates neutrophil production while EPO stimulates red blood cell production, together enhancing hematopoietic recovery and tissue oxygenation. Used for Decompensated liver cirrhosis with bone marrow dysfunction, Hepatic encephalopathy with hematologic complications.
At a glance
| Generic name | G-CSF+EPO |
|---|---|
| Sponsor | Institute of Liver and Biliary Sciences, India |
| Drug class | Hematopoietic growth factor combination |
| Target | G-CSF receptor (GCSFR) and Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology / Hepatology |
| Phase | Phase 3 |
Mechanism of action
Granulocyte-Colony Stimulating Factor (G-CSF) acts on hematopoietic progenitor cells to promote neutrophil differentiation and mobilization, while Erythropoietin (EPO) stimulates erythroid progenitors to increase red blood cell production. The combination aims to synergistically restore bone marrow function and improve oxygen delivery, potentially beneficial in conditions with compromised hematopoiesis such as liver disease or cirrhosis.
Approved indications
- Decompensated liver cirrhosis with bone marrow dysfunction
- Hepatic encephalopathy with hematologic complications
Common side effects
- Bone pain
- Hypertension
- Thrombosis
- Splenomegaly
Key clinical trials
- Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease (PHASE2)
- Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer) (PHASE2)
- National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis (NA)
- Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis. (NA)
- Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes (PHASE3)
- Therapeutic Use of Angiopoietin-Primed Autologous Peripheral Blood Stem Cell in Myocardial Infarction (PHASE3)
- Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
- Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |